Perspective Therapeutics, Inc. (CATX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Perspective Therapeutics, Inc. (CATX) Healthcare & Pipeline Overview

Perspective Therapeutics, Inc., operating in the medical device sector, specializes in isotope-based cancer treatments, particularly Cesium-131 brachytherapy seeds. Targeting prostate, brain, and lung cancers, the company sells to surgical facilities and physician practices, distinguishing itself through specialized radiation therapy solutions in a competitive healthcare market.

What Is the Investment Thesis for CATX?

Perspective Therapeutics, Inc. presents a focused investment opportunity within the medical device sector, specifically in isotope-based cancer treatments. The company's core value driver is the continued adoption and expansion of CS-1 Cesium-131 brachytherapy seeds in treating various cancers. Growth catalysts include ongoing clinical trials and regulatory approvals for new applications of Cesium-131. However, potential risks include the company's negative profit margin of -12261.7% and gross margin of -166.3%, indicating significant financial challenges. The company's high beta of 1.87 suggests higher volatility compared to the market. Successful execution of clinical and commercial strategies is crucial for realizing the company's potential.

Based on FMP financials and quantitative analysis

CATX Key Highlights

Market Cap of $366M reflects its valuation in the medical device market.

• Profit Margin of -12261.7% indicates significant losses and operational inefficiencies.
• Gross Margin of -166.3% highlights challenges in covering the cost of goods sold.
• Beta of 1.87 suggests the stock is more volatile than the market.
• Focus on Cesium-131 brachytherapy seeds positions it in a niche market within cancer treatment.

Who Are CATX's Competitors?

CATX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CATX's Key Strengths?

Specialized in Cesium-131 brachytherapy seeds.

• Targeted approach to cancer treatment.
• Established presence in the brachytherapy market.
• Experienced management team.

What Are CATX's Weaknesses?

Negative profit and gross margins.

• Limited product portfolio.
• Reliance on a single product line.
• High beta indicating volatility.

What Could Drive CATX Stock Higher?

Clinical trial results for Cesium-131 in new cancer types.

• Regulatory approvals for expanded indications of Cesium-131.
• Expansion of sales and marketing efforts in key geographic markets.
• Development of new brachytherapy techniques.

What Are the Key Risks for CATX?

Financial-distress signal — its Altman Z-Score of 1.73 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-41.8%) — the business is not currently generating profit on shareholder capital.
• Competition from larger medical device companies.
• Regulatory challenges and compliance requirements.
• Negative profit and gross margins.
• Reliance on a single product line.

What Are the Growth Opportunities for CATX?

• Expansion into New Therapeutic Areas: Perspective Therapeutics has the opportunity to expand the application of its Cesium-131 brachytherapy seeds into new cancer types. This includes exploring its efficacy in treating cancers such as breast cancer and pancreatic cancer. The market for these therapies is substantial, with the global breast cancer therapeutics market projected to reach $39.7 billion by 2027. Clinical trials and regulatory approvals will be essential for this expansion, offering a significant growth avenue over the next 3-5 years.
• Geographic Market Expansion: Perspective Therapeutics can pursue growth by expanding its geographic footprint beyond the United States. International markets, particularly in Europe and Asia, offer significant opportunities for growth. The global radiation therapy market is expected to reach $8.7 billion by 2028. Entering these markets requires navigating regulatory hurdles and establishing distribution networks, but the potential revenue growth is substantial over the next 3-5 years.
• Strategic Partnerships and Acquisitions: Perspective Therapeutics can grow through strategic partnerships and acquisitions. Collaborating with other companies in the cancer treatment space can provide access to new technologies, markets, and expertise. Acquiring complementary businesses can expand the company's product portfolio and market share. These partnerships and acquisitions can be pursued over the next 2-3 years, driving growth and innovation.
• Development of Novel Isotopes: Perspective Therapeutics can invest in the development of new isotopes for cancer treatment. This includes researching and developing isotopes with improved efficacy, safety, and targeting capabilities. The market for novel isotopes is growing, driven by the demand for more effective cancer therapies. This research and development effort can yield significant long-term growth opportunities over the next 5-10 years.
• Advancements in Brachytherapy Techniques: Perspective Therapeutics can focus on advancing brachytherapy techniques to improve treatment outcomes. This includes developing new methods for delivering Cesium-131 seeds, such as image-guided brachytherapy and robotic-assisted brachytherapy. These advancements can enhance the precision and effectiveness of brachytherapy, leading to better patient outcomes and increased adoption. These improvements can be implemented over the next 2-4 years, enhancing the company's competitive edge.

What Threats Does CATX Face?

• Competition from larger medical device companies.
• Regulatory hurdles and compliance requirements.
• Technological advancements by competitors.
• Economic downturn affecting healthcare spending.

What Are CATX's Competitive Advantages?

• Specialized expertise in isotope-based cancer treatments.
• Proprietary Cesium-131 brachytherapy seed technology.
• Established relationships with surgical facilities and physician practices.

What Does CATX Do?

Perspective Therapeutics, Inc., originally founded as Isoray, Inc. in 1998 and rebranded in February 2022, is a medical device company focused on developing, manufacturing, and marketing isotope-based medical products for cancer treatment. The company's core product is CS-1 Cesium-131 brachytherapy seeds, which are used in brachytherapy, a form of radiation therapy where radioactive sources are placed inside the body to target cancer cells directly. These seeds are primarily used in the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. Perspective Therapeutics sells its products to facilities and physician practices that utilize surgical facilities, both in the United States and internationally. The company is based in Richland, Washington, and operates with a team of 138 employees. The rebranding to Perspective Therapeutics reflects the company's broader vision and strategic focus on expanding its portfolio of targeted cancer therapies.

What Products and Services Does CATX Offer?

• Develops isotope-based medical products.
• Manufactures Cesium-131 brachytherapy seeds.
• Sells cancer treatment devices.
• Markets products internationally.
• Offers brachytherapy solutions for various cancers.
• Targets prostate, brain, lung, and other cancers.

How Does CATX Make Money?

• Develops and manufactures Cesium-131 brachytherapy seeds.
• Sells products to surgical facilities and physician practices.
• Generates revenue through direct sales of medical devices.

What Industry Does CATX Operate In?

Perspective Therapeutics operates in the medical device industry, which is characterized by technological innovation, stringent regulatory requirements, and intense competition. The market for cancer treatment devices is growing, driven by an aging population and increasing cancer incidence rates. Key trends include the development of more targeted and personalized therapies. Perspective Therapeutics competes with larger medical device companies and specialized radiation therapy providers. The company's focus on isotope-based treatments positions it within a niche segment of the broader cancer therapy market.

Who Are CATX's Key Customers?

• Hospitals and cancer treatment centers.
• Physician practices specializing in oncology.
• Surgical facilities utilizing brachytherapy.

Wall Street analysts project Perspective Therapeutics, Inc. revenue of about $374K for fiscal 2026, with EPS near $-1.09. The estimate reflects 10 contributing analysts.

Perspective Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.73 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Perspective Therapeutics, Inc. stands at -41.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -46.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.75 indicates the company holds enough short-term assets to cover its near-term obligations.

Perspective Therapeutics, Inc. (CATX) Valuation Context

Valued at $366M, CATX is classified as a small-cap stock. Relative to its peer group, CATX's quantitative score of 19/100 is below the peer average of 75/100.

CATX Revenue & Earnings Trend

In Q2 2026, CATX generated $81K in top-line revenue, marking a sequential increase of 6.6%. The company recorded a net loss of $26.8M, with diluted EPS of $-0.22. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, CATX averaged $-0.36 in diluted EPS.

Company Profile

Perspective Therapeutics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Johan Spoor. CATX has traded publicly since 2005.

CATX Financials

CATX Latest News

CATX Analyst Consensus

CATX MoonshotScore

Common Questions About CATX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources